Dendritic cell vaccine therapy of cutaneous melanoma after the radical surgery
Abstract
Dendritic cell vaccine therapy induces activation of antitumor immune response, which in some cases can cause tumor regression even in advanced melanoma patients. Vaccine therapy after surgical treatment for prevention of tumor recurrence may be more effective. In this trial we present results for clinical and immunological effectiveness of dendritic vaccine therapy of stage III–IV cutaneous melanoma after surgical treatment.
About the Authors
N. N. Petenko
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
I. N. Mikhailova
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
G. Z. Chkadua
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
L. V. Demidov
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
A. U. Barishnikov
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
References
1. Boon T., Coulie P.G., van Den Eynde B.J. et al. Human T-cell responses against melanoma. Ann. Rev. Immunol. 2006, v. 24, p. 175-208.
2. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 1998, v. 392 (6673), p. 245-252.
3. Fong L., EnglemanE.G. Dendritic cells in cancer immunotherapy. Ann. Rev. Immunol. 2000, v. 18, p. 245-273.
4. Гантиевская Ю.А., Селявко В.В. Дендритные клетки: роль в системе иммунитета. Иммунопатология, аллергология, инфектология. 2001, № 4, с. 5-23.
5. Janeway C., Walport M.J., Travers P. Immunobiology: The immune system in health and disease. 6th ed. 2001, New York: Garland Science. 823.
6. Almand B., Resser J.R., Lindman B. et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000, v. 6 (5), p. 1755-1766.
7. Gabrilovich D.I., Corak J., Ciernik I.F. et al. Gabrilovich D.I. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 1997, v. 3 (3), p. 483-490.
8. Nestle F.O., Alijagic S., Gilliet M. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 1998, v. 4 (3), p. 328-332.
9. O’Rourke M.G., JohnsonM., Lanagan C. et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. 2003, v. 52 (6), p. 387-395.
10. Guo H.B., Stoffel-Wagner B., Bierwirth T. et al. Clinical significance of serum S100 in metastatic malignant melanoma. Eur. J. Cancer. 1995, v. 31A (11), p. 1898-1902.
11. Jury C.S., Mcallister E.J., Mackie R.M. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br. J. Dermatol. 2000, v. 143 (2), p. 269-274.
12. Демидов Л.В., ХаркевичГ.Ю. Меланома кожи: стадирование, диагностика и лечение. Русский медицинский журнал. 2003, № 11 (11), с. 658-665.
13. Dummer R., Hauschild A., Guggenheim M. et al. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010, v. 21 (suppl. 5), p. 194-197.
14. Marsden J.R., Newton-Bishop J.A., Burrows L. et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br. J. Dermatol. 2010, v. 163 (2), p. 238-256.
15. Kirkwood J.M., Manola J., Ibrahim J. et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 2004, v. 10 (5), p. 1670-1677.
16. Чкадуа Г.З., Заботина Т.Н., Буркова А.А. Адаптирование методики культивирования дендритных клеток человека из моноцитов периферической крови для клинического при- менения. Российский Биотерапевтический Журнал. 2002, № 1 (3), с. 56-59.
17. Balch C.M., Soong S.J., Gershenwald J.E. et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 2001, v. 19 (16), p. 3622-3634.
18. Homsi J., Kashani-Sabet M., Messina J.L. et al. Cutaneous melanoma: prognostic factors. Cancer Control. 2005, v. 12 (4), p. 223-229.
19. Sobin L.H., Gospodarowicz M.K., Wittekind C. et al. TNM classification of malignant tumours. 7th ed. 2010. Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell. XX, 309.
Review
For citations:
Petenko N.N., Mikhailova I.N., Chkadua G.Z., Demidov L.V., Barishnikov A.U. Dendritic cell vaccine therapy of cutaneous melanoma after the radical surgery. Bone and soft tissue sarcomas, tumors of the skin. 2015;(1):43-49. (In Russ.)
Views:
115
Email this article 
